The starting point of the investigation was a computational strategy known as network toxicology, which treats a chemical, its protein targets, and human disease genes as nodes in an interconnected graph rather than as isolated entities. The researchers first assembled a comprehensive list of proteins that benzo[a]pyrene is known or predicted to interact with, drawing on established toxicogenomic databases and target-prediction tools. They then cross-referenced this list with genes associated with prostate cancer. The overlap was striking: 975 shared targets emerged, suggesting that BaP and prostate tumors converge on an unexpectedly large common molecular territory. When these 975 genes were mapped onto known biological pathways, the enrichment analysis pointed decisively toward the PI3K-Akt signaling axis, one of the most frequently hijacked growth and survival circuits in human malignancy, along with related networks governing cell proliferation, apoptosis resistance, and immune modulation.

Identifying 975 candidate genes is a useful beginning, but cancer biology demands sharper focus. To distill the signal, the team applied differential expression analysis to prostate cancer transcriptomic data and then deployed machine learning algorithms to select which of the differentially expressed genes best separated tumor from healthy tissue. Two complementary algorithms converged on four core genes: CAV1, TWIST1, PRKCA, and GDF15. Each of these has an established biography in cancer research. CAV1 encodes caveolin-1, a scaffolding protein of membrane caveolae with documented roles in prostate cancer progression and treatment resistance. TWIST1 is a transcription factor best known for orchestrating epithelial-to-mesenchymal transition, the cellular program that allows stationary epithelial cells to become invasive and migratory. PRKCA encodes protein kinase C alpha, described in recent work as a central node of tumorigenic transcriptional networks in the prostate. GDF15, or growth differentiation factor 15, is a stress-response cytokine whose levels correlate with aggressive and castration-resistant disease.

With the four core genes in hand, the investigators turned to transcriptomic verification. The expression pattern in prostate tumor datasets was coherent and directional: TWIST1 and GDF15 were up-regulated in cancer tissue, while CAV1 and PRKCA were down-regulated. More impressive was the diagnostic performance. When the four genes were combined into a single diagnostic model, the area under the receiver operating characteristic curve reached 0.990, a value approaching the theoretical maximum of 1.0 and indicating near-perfect discrimination between cancerous and non-cancerous samples. The authors emphasize that this four-gene signature could distinguish BaP-relevant molecular states in prostate tissue with a precision that single biomarkers rarely achieve, positioning the panel as both a mechanistic fingerprint of pollutant-driven carcinogenesis and a candidate clinical diagnostic tool.

Because tumors are not merely collections of malignant cells but complex ecosystems of immune, stromal, and epithelial populations, the team next examined how the core genes behave at single-cell resolution. Single-cell RNA sequencing data revealed the specific cellular distribution of each gene within the prostate tumor microenvironment and documented immunological shifts associated with their expression. Immune infiltration analysis at the bulk-tumor level reinforced the connection: the core genes were linked to cellular growth programs and to the recruitment of immune cells into tumors. This immunological dimension matters because previous research has suggested that BaP exposure can play an immunosuppressive role during prostate cancer progression, potentially helping tumors evade surveillance. The new findings place that immune remodeling on a firmer molecular footing, tying it to genes that are themselves responsive to BaP exposure.

To test whether the carcinogen could physically engage its putative targets, the researchers performed molecular docking, a computational technique that predicts how a small molecule fits into the binding pocket of a protein. The docking simulations showed that benzo[a]pyrene binds favorably to the core targets, providing a structural rationale for the associations uncovered by the network analysis. Docking results are inherently approximate and do not prove physiological binding in living cells, but within the study’s multi-layered design they serve as an important plausibility check, bridging the gap between statistical gene associations and the physical chemistry of pollutant-protein interactions.

Perhaps the most consequential portion of the work is its external validation. Computational pipelines in toxicology are sometimes criticized for generating elegant networks that evaporate under experimental scrutiny, so the authors tested their predictions with laboratory and dataset evidence outside the discovery pipeline. The validation confirmed that BaP may promote the progression of prostate cancer and reproduced the expected expression shifts: GDF15 up-regulated and PRKCA down-regulated in prostate cancer contexts linked to BaP exposure. The convergence of the computational prediction and the external evidence strengthens the causal narrative considerably, indicating that the four-gene axis is not an artifact of a single database or analytical choice but a reproducible molecular pattern.

The study arrives amid a growing wave of network toxicology applied to environmental carcinogens in urological cancers. Recent publications have used similar frameworks to implicate polycyclic aromatic hydrocarbons in reproductive health outcomes, to trace the oncogenic pathways of aristolochic acids across prostate, kidney, and bladder cancers, and to dissect the contributions of phthalates such as diethyl phthalate and DEHP to prostate carcinogenesis. Epidemiological work has also lent real-world weight to the hypothesis: occupational exposure to polycyclic aromatic hydrocarbons has been associated with elevated prostate cancer risk in case-control studies. What distinguishes the new paper is the breadth of its validation stack, extending from machine-learning biomarker selection through single-cell immunology to molecular docking and external experimental confirmation, all focused on a single Group 1 carcinogen that nearly every person encounters daily through diet, air, and tobacco smoke.

The implications cut in two directions. Clinically, a four-gene diagnostic panel with an AUC of 0.990 suggests that pollutant-driven molecular signatures could eventually complement prostate-specific antigen testing, which suffers from well-documented problems of overdiagnosis and poor specificity. If GDF15, for example, is already being explored as a circulating marker of response to docetaxel chemotherapy in metastatic castration-resistant prostate cancer, integrating exposure-linked gene panels into diagnostic algorithms could help identify which tumors are environmentally fueled and potentially which patients might benefit from interventions targeting the PI3K-Akt pathway, where several inhibitors are already under investigation in hormone-related cancers. Public health officials, meanwhile, may find in these results additional mechanistic justification for limiting BaP exposure through food preparation guidance, tobacco control, and air quality regulation, since the molecular evidence now traces a plausible route from charred protein and diesel soot to the transcriptional circuits of prostate tumors.

The authors are careful about scope. Their conclusions are framed as BaP potentially promoting prostate cancer development through regulation of CAV1, TWIST1, GDF15, and PRKCA, with causal certainty limited by the correlative nature of much of the transcriptomic evidence and by the approximate nature of docking predictions. The DU145 prostate cancer cell line used in their experiments is commercially available, and the study received support from the Guizhou Provincial Health Commission and related provincial research programs. Still, the work exemplifies a methodological shift that is transforming environmental oncology: instead of asking whether a chemical damages DNA, researchers now map the full network of its molecular conversations with human tissue, then test the strongest nodes experimentally. For a carcinogen as widespread as benzo[a]pyrene, and a cancer as prevalent as prostate cancer, that map may prove to be one of the most valuable public health documents of the decade.

Subject of Research: Molecular mechanisms linking benzo[a]pyrene exposure to prostate cancer

Article Title: Exploring the molecular mechanism of benzo[a]pyrene affecting prostate cancer based on network toxicology and external validation

Article References: Zhu, S., Li, Z., Jiang, K., Sun, F., & Zhu, J. (2026). Exploring the molecular mechanism of benzo[a]pyrene affecting prostate cancer based on network toxicology and external validation. Molecular Diversity. https://doi.org/10.1007/s11030-026-11729-6

Image Credits: AI Generated

DOI: 10.1007/s11030-026-11729-6

Keywords: benzo[a]pyrene, prostate cancer, network toxicology, machine learning, CAV1, TWIST1, PRKCA, GDF15, PI3K-Akt pathway, single-cell analysis, molecular docking, environmental carcinogens

The researchers set out to close a major gap in kinome pharmacology. Protein kinases—the 518 enzymes that phosphorylate most human proteins and orchestrate nearly every cellular process—are not merely catalytic cores. Beyond their conserved kinase domains, they carry additional domains that mediate autoinhibition, subcellular localization, and complex formation. Autoinhibitory domains (AIDs) typically keep kinases dormant by docking onto the kinase domain and masking the ATP-binding site, blocking both enzymatic activity and substrate interactions until an activating signal relieves this restraint. Classical structural methods struggle to characterize these domains because many AIDs are intrinsically disordered or connected to the catalytic core through flexible linkers, and most structural studies rely on truncated, purified recombinant proteins that lack the physiological post-translational modifications and binding partners essential for correct function. Whether ATP-competitive inhibitors, which stabilize the active DFG-in conformation of the kinase domain, also force structural changes at the AID remained a poorly explored dark space.

To address this, the team developed a multimodal proteomics strategy combining three complementary mass spectrometry-based approaches. The first, AP-LiP-MS, applies limited proteolysis coupled to mass spectrometry on affinity-purified samples: kinases are purified from human cells under native conditions, treated with an inhibitor, and then exposed to proteinase K, which preferentially cleaves accessible and flexible regions. Changes in the resulting conformation-specific peptide fragments reveal structural shifts with high sequence coverage while preserving the native cellular context. This structural readout was paired with contextual proteomics—affinity purification mass spectrometry (AP-MS) to measure complex formation and in vivo proximity labeling using the miniTurbo biotin ligase to map the kinase’s biochemical neighborhood in living cells. The approach was first benchmarked on the kinase DCLK1, where known X-ray crystal structures of the autoinhibited and inhibitor-bound states confirmed that AP-LiP-MS faithfully detects the anticipated structural rearrangements.

Applying the workflow to three disease-associated kinases with well-characterized ATP-competitive inhibitors—CAMKK2 targeted by SGC-CAMKK2-1, CHEK1 targeted by rabusertib, and PRKCA targeted by Gö 6983—the researchers found a striking common theme. In every case, inhibitor binding produced structural changes precisely at the autoinhibitory domain, with increased proteinase K susceptibility indicating that the AID becomes more solvent-exposed. This is consistent with the AID dissociating from the kinase domain, driving the inhibited enzyme into an open, active-like conformation that mimics the structural unlocking that occurs during normal kinase activation. Notably, a structurally similar negative control compound that does not bind CAMKK2 induced neither structural nor interaction changes, confirming the specificity of the observations. For PRKCA, structural alterations extended into the membrane-binding C2 domain, specifically at a short regulatory segment associated with autoinhibition, hinting that multiple domain-domain interactions are disrupted by drug binding.

The consequences of these conformational shifts proved to be as diverse as they were unexpected. For CAMKK2, the inhibitor stabilized a complex between CAMKK2 and PRKAA1, the catalytic subunit of the AMPK energy-sensing complex. Catalytically inactive and autonomously active CAMKK2 mutants responded to the drug with the same interaction pattern, demonstrating that the effect depends on the conformational change rather than on catalytic inhibition. Structural modeling with AlphaFold3 suggested that the activation-relevant T183 residue of PRKAA1 becomes buried within the predicted CAMKK2–PRKAA1 interface. Functional experiments confirmed the implication: in glucose-starved cells, SGC-CAMKK2-1 reduced T183 phosphorylation of PRKAA1 by upstream kinases such as LKB1, and this suppression was rescued when CAMKK2 was depleted by siRNA. In other words, the inhibited kinase acts as a physical shield that sequesters AMPK and blocks its activation through an entirely non-catalytic, scaffolding mechanism—potentially shutting down both the calcium-dependent and energy-stress branches of AMPK signaling simultaneously.

Strikingly, a disease-associated CAMKK2 variant, the R311C mutation found in a patient with bipolar disorder, completely abolished the inhibitor-induced interaction with PRKAA1. Because R311 faces the predicted interaction interface while the neighboring catalytic residue D312 lies outside it, the finding offers the first mechanistic clue for how this genetic variant may uncouple the CAMKK2–AMPK signaling axis in patients, and it underscores that drug responses can depend critically on the specific disease variant a patient carries—a consideration for personalized medicine.

The second model kinase, CHEK1, revealed a different flavor of paradox. Rabusertib remodeled CHEK1’s interactions with numerous DNA-damage response proteins, increasing binding to 14-3-3 proteins, the deubiquitylating enzyme USP7, PCNA, and MCM replication licensing factors, and elevating phosphorylation at the ATR-targeted S317 site—changes mirroring those seen during genuine DNA damage-induced activation. The single interactor that dissociated was CLPB, a mitochondrial protein previously identified in multiple studies as a CHEK1 partner. CLPB dissociation occurred in both wild-type and catalytically inactive CHEK1 but not in a constitutively open mutant, again implicating the conformational rather than catalytic consequence of inhibition. Because CLPB loss is known to cause mitochondrial fragmentation, the researchers examined mitochondrial morphology by super-resolution microscopy. Rabusertib treatment significantly increased mitochondrial fragmentation, an effect that persisted even when the canonical CDK1–DRP1 fragmentation pathway was blocked with the CDK1 inhibitor RO-3306, and that could not be reproduced by DNA damage alone. While a direct causal link between CHEK1–CLPB dissociation and fragmentation remains to be established, the data suggest that CHEK1 inhibition may disrupt mitochondrial proteostasis through a mechanism independent of the drug’s intended catalytic target.

The third model, PRKCA, demonstrated how inhibitor-induced structural changes can redirect a kinase within the cell. Upon Gö 6983 binding, proximity labeling revealed a rapid shift of PRKCA toward membrane-associated proteins at cell junctions, including tight junction, adherens junction, and desmosome components, as well as the known interactor integrin beta-1. Calcium imaging ruled out changes in intracellular calcium as the driver, and a dose-response experiment showed that these junctional proximity changes occurred at significantly lower drug concentrations than other effects, consistent with a specific on-target mechanism. Catalytically inactive and constitutively active PRKCA mutants responded identically, confirming the phenotype is independent of catalytic inhibition. Live-cell imaging of EGFP-tagged PRKCA captured the kinase relocating to the cell periphery—particularly cell-cell contact sites—within eight minutes of drug addition. The researchers propose that Gö 6983 binding opens the C2 domain, exposing a lysine cluster that can bind the junctional lipid PIP2, thereby recruiting the inhibited kinase to membranes through a calcium-independent route.

Taken together, the study establishes the ATP-binding site as a major organizing center of kinase conformation and interaction, and suggests that inhibitor-induced non-catalytic gain-of-function is likely far more prevalent among kinases with autoinhibitory domains than currently appreciated. The authors point to existing examples such as the JAK2 inhibitor ruxolitinib, which paradoxically primes JAK2 hyperphosphorylation and contributes to side effects after drug withdrawal, and BRAF inhibitors that allosterically promote RAF dimerization and MAPK activation, as evidence that such mechanisms already matter clinically. Because many AID-mediated effects would be missed by conventional target engagement assays focused on catalytic kinetics, the authors advocate for systematic multimodal proteomic profiling of both wild-type and disease-mutant kinases during early drug development. The combination of structural and contextual proteomics is not restricted to kinases and could extend to targets lacking catalytic activity altogether. By mapping inhibitor-modulated conformational and interactome landscapes early, researchers hope to detect unexpected liabilities before they surface in the clinic, ultimately guiding the design of safer and more effective kinase-targeted therapeutics.

Subject of Research: Inhibitor-induced displacement of kinase autoinhibitory domains driving non-catalytic drug effects

Article Title: Paradoxical non-catalytic kinase functions are driven by inhibitor-induced displacement of autoinhibitory domains

Article References: Reber, V., Keller, S., Loosli, S. A., Arima, Y., Kleele, T., Picotti, P., & Gstaiger, M. (2026). Paradoxical non-catalytic kinase functions are driven by inhibitor-induced displacement of autoinhibitory domains. Molecular Systems Biology, 22(9), 1474-1500. https://doi.org/10.1038/s44320-026-00229-2

Image Credits: AI Generated

DOI: 10.1038/s44320-026-00229-2

Keywords: kinase inhibitors, autoinhibitory domains, proteomics, protein-protein interactions, CAMKK2, CHEK1, PRKCA, AMPK, mitochondrial fragmentation, drug mechanisms, conformational change, Molecular Systems Biology